NEW YORK (TheStreet) -- Shares of FUJIFILM Holdings Corp. aare up 3.83% to $34.99 after it was reported that athe company, which is mainly engaged in the provision of imaging, information and document solutions,awill acquire an American maker of vaccines to order, gaining a foothold in a business with the prospect of global growth, the Nikkei Asian Review reports. The Fujifilm Holdings unit will buy 49% of Kalon Biotherapeutics from founder Texas A&M University and the state of Texas in a deal estimated at several billion yen. Fujifilm intends to acquire all of Kalon eventually, the Nikkei said. Founded in 2011, Kalon can safely handle and produce vaccines against some of the world's deadliest pathogens, including anthrax. It has received roughly $170 million in U.S. government subsidies and been designated by Washington as a key treatment provider in the event of bioterrorist attacks or other public health emergencies, Nikkei noted. Must Read: Warren Buffett's 25 Favorite Stocks STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. a Fujifilm, once among the world's biggest makers of camera film, has been busy expanding its presence in pharmaceuticals. It has drawn attention of late for an influenza drug that has been drafted for the fight against Ebola, Nikkei added. FUJIY data by YCharts STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Click to view a price quote on FUJIY.
from Latest TSC Headlines http://ift.tt/1oQnxTS
No comments:
Post a Comment